AbbVie has entered into a licensing deal with Gilgamesh Pharmaceuticals to develop new treatments for psychiatric disorders. AbbVie will pay Gilgamesh an upfront payment of $65 million and up to $1.95 billion in potential milestones. Gilgamesh is developing drugs known as neuroplastogens, which aim to provide clinical benefits without the psychoactive side effects of existing medications. AbbVie will take the lead on developing and commercializing the drugs. This deal is part of a string of recent deals and acquisitions by AbbVie.

Read Press Release, Crains, Endpoints

This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox.